Table 3.

Associations of baseline fibroblast growth factor 23 concentrations with annualized change in eGFR in the HALT-PKD Study A and Study B

Mean Annualized Change in eGFR (95% CI)
Study AP Value TrendStudy BP Value Trend
Unadjusted
 FGF23 quartile 1−2.51 (−2.71 to −2.30)<0.001−2.78 (−2.92 to −2.63)<0.001
 FGF23 quartile 2−2.74 (−3.24 to −2.25)−3.36 (−3.72 to −3.00)
 FGF23 quartile 3−3.13 (−3.63 to −2.64)−3.37 (−3.75 to −2.99)
 FGF23 quartile 4−3.62 (−4.12 to −3.12)−3.74 (−4.14 to −3.34)
Adjusteda
 FGF23 quartile 1−2.39 (−2.60 to −2.10)<0.001−2.74 (−2.89 to −2.59)<0.001
 FGF23 quartile 2−2.81 (−3.33 to −2.39)−3.31 (−3.69 to −2.94)
 FGF23 quartile 3−3.17 (−3.70 to −2.64)−3.35 (−3.74 to −2.96)
 FGF23 quartile 4−3.63 (−4.16 to −3.10)−3.78 (−4.19 to −3.36)
  • 95% CI, 95% confidence interval; FGF23, fibroblast growth factor 23.

  • a Adjusted for age, sex, body mass index, systolic BP, randomization group, calcium, phosphorus, eGFR, urinary albumin excretion, and polycystic kidney disease genotype.